- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03373019
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
December 12, 2017 updated by: Kai Xue, MD, Fudan University
A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation
The goal of this clinical trial is to evaluate therapeutic efficacy of Chidamide combined with R-GDP (rituximab/gemcitabine/dexamethasone/cisplatin)in treating Patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not suitable for transplantation.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The treatment outcome of patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) are not satisfactory especially for those not suitable for transplantation.
One of main reason is chemotherapy resistance.
The investigators conducted this study to evaluate the efficacy of Chidamide combined with R-GDP(rituximab/gemcitabine/dexamethasone/cisplatin) in treating patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not suitable for transplantation.
Chidamide is a novel benzamide type of subtype-selective histone deacetylase (HDAC) inhibitor.
It has been approved by China Food and Drug Administration (CFDA) for treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in Chinese population.
The investigators' pre-clinical data suggested that this agent might be also efficient in the treatment of relapsed/refractory B cell lymphoma.
In this open-label, non-randomized, phase II study, the investigators aimed to observe the efficacy and safety of chidamide combined with R-GDP in patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) not suitable for transplantation.
Study Type
Interventional
Enrollment (Anticipated)
63
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kai Xue, MD
- Phone Number: 13818659448
- Email: xuekaishanghai@126.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Kai Xue
-
Contact:
- Kai Xue, MD
- Phone Number: 13818659448
- Email: xuekaishanghai@126.com
-
Contact:
- Junning Cao, MD
- Phone Number: 13818659448
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Kai Xue
-
Contact:
- Kai Xue, MD
- Phone Number: 13818659448
- Email: xuekaishanghai@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages: 18-75 years old
- Relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) previous treated with standard chemoimmunotherapy
- Not willing or not suitable for hematopoietic stem cell transplantation (HSCT)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) index < 2
- Informed consent available
- Life expectancy of more than 3 months;
- Ultrasonic cardiogram showed left ventricle ejection fraction ≥ 50%, EKG showed on signs of myocardial ischemia, with no previous arrhythmia which need pharmacological intervention.
- Bone marrow function: ANC ≥ 1.5 × 109/L, PLT ≥ 100 × 109/L, Hb ≥ 80g/L;
- Liver function: total bilirubin, ALT and AST were <1.5 × UNL (the upper limit of normal value)
- Renal function: Cr<1.5 × UNL and creatinine clearance > 50ml/min
Exclusion Criteria:
- Prior history of treatment of HDAC inhibitor.
- Plan of HSCT in the future
- Significant pericardial effusion showed by chest CT scan
- Prior history of other cancers except treated cervical or basal cell skin carcinoma, organ transplantation
- Syphilis or human immunodeficiency virus (HIV) infection
- Pregnant or lactating women
- History of organ transplantation
- Serious active infections (including hepatitis)
- Serious neurological or psychiatric history, including dementia or epilepsy.
Termination criteria:
- Withdrew consent
- Researchers think it is necessary to terminate the study;
- Disease progression or death;
- Poor compliance
- Subclinical or clinical cardiac toxicity;
- Unable to continue treatment because of severe toxicity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Chidamide combined with R-GDP
Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
|
Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: 6 weeks
|
overall response rate
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: 3 years
|
overall survival
|
3 years
|
3 year PFS
Time Frame: 3 years
|
3 year progression free survival
|
3 years
|
adverse event
Time Frame: throughout the treatment period,up to 6 months
|
adverse event related to treatment
|
throughout the treatment period,up to 6 months
|
CR
Time Frame: 6 weeks
|
complete response
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
December 21, 2017
Primary Completion (ANTICIPATED)
June 30, 2019
Study Completion (ANTICIPATED)
March 1, 2021
Study Registration Dates
First Submitted
November 30, 2017
First Submitted That Met QC Criteria
December 12, 2017
First Posted (ACTUAL)
December 14, 2017
Study Record Updates
Last Update Posted (ACTUAL)
December 14, 2017
Last Update Submitted That Met QC Criteria
December 12, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CC-RD1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
European Association for Endoscopic SurgeryWithdrawn
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on Chidamide combined with R-GDP
-
Sun Yat-sen UniversityRecruitingTriple Negative Breast CancerChina
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingFollicular Lymphoma | Relapsed Non-Hodgkin Lymphoma | Refractory B-Cell LymphomaChina
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Peking Union Medical College HospitalRecruitingPeripheral T Cell LymphomaChina
-
Peking Union Medical College HospitalRecruitingCutaneous T-cell LymphomaChina
-
Fudan UniversityCompletedCisplatin | Adenoid Cystic CarcinomasChina
-
Sun Yat-sen UniversityRecruitingPeripheral T-Cell Lymphoma With Follicular Helper of T Cell PhenotypeChina
-
Fudan UniversityRecruitingTriple-negative Breast CancerChina
-
Ruijin HospitalRecruiting